Prime Medicine's application will test an FDA that has promised to speed new gene-editing treatments but has recently spurned ...

The firm believes that clinical data generated to date from two patients may be sufficient to support accelerated approval of PM359.

Discover how prime editing is redefining the future of medicine by offering highly precise, safe, and versatile DNA corrections, bringing hope for more effective treatments for genetic diseases while ...

CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, ...

SAN FRANCISCO—Prime Medicine is on track to file the first IND/CTA application for human trials of a prime editing therapy to the FDA during the first half of this year, with the first clinical data ...

On track to file IND and/or CTA for Wilson Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both ...

Clustered, regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9 (CRISPR-Cas9) are genome editing tools. 1 After their potential in therapeutics was recognized, ...

While researchers have long appreciated the enormous potential of genome editing to treat disease, applications of these technologies in humans have historically been limited by safety concerns. Even ...

In a study published in Nature Biotechnology, GAO Caixia's group from the Institute of Genetics and Developmental Biology of the Chinese Academy of Sciences has developed a series of new prime editors ...

Like the human immune system, bacteria learn from past infections. CRISPR sequences—short snippets of DNA from previous viruses—guide destructive enzymes towards invading bacteriophages that express ...